Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management
Description
CONCLUSION: Two of 4 patients with VITT developed refractory thrombocytopenia successfully treated with intravenous immunoglobulin, corticosteroids, and plasma exchange therapy. Patients with VITT remained on anticoagulation for at least 9 months due
